René Böttcher

René Böttcher

Auto-generated profile, based on publicly available information

René Böttcher

Cell Signaling Research Group, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), E-08003 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in European Urology
Verified
Journal Article
Closed access
EMElena S. Martens-Uzunova
Elena S. Martens-Uzunova
RBRené Böttcher
René Böttcher
CCCarlo M. Croce
Carlo M. Croce
GJGuido Jenster
Guido Jenster
TVTapio Visakorpi
Tapio Visakorpi
George CalinGeorge Calin
George Calin

1 July 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
MSMatthias Schewe
Matthias Schewe
PFPatrick F. Franken
Patrick F. Franken
ASAndrea Sacchetti
Andrea Sacchetti
MSMark Schmitt
Mark Schmitt
RJRosalie Joosten
Rosalie Joosten
Riccardo FoddeRiccardo Fodde
Riccardo Fodde

31 January 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LELale Erdem-Eraslan
Lale Erdem-Eraslan
MBMartin J. Van Den Bent
Martin J. Van Den Bent
YHYouri Hoogstrate
Youri Hoogstrate
HNHina Naz-Khan
Hina Naz-Khan
ASAndrew Stubbs
Andrew Stubbs
PFPim French
Pim French
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM). In this study, we performed gene expression profiling (DASL and RNA-seq) of formalin-fixed, paraffin-embedded tumor material from participants of the BELOB trial to identify patients with recurrent GBM who benefitted most from beva+CCNU treatment. We demonstrate that tumors assigned to the IGS-18 or “classical” subtype and treated with beva+CCNU showed a significant benefit in progression-free survival and a trend toward benefit in overall survival, whereas other subtypes did not exhibit such benefit. In particular, expression of FMO4 and OSBPL3 was associated with treatment response. Importantly, the improved outcome in the beva+CCNU treatment arm was not explained by an uneven distribution of prognostically favorable subtypes as all molecular glioma subtypes were evenly distributed along the different study arms. The RNA-seq analysis also highlighted genetic alterations, including mutations, gene fusions, and copy number changes, within this well-defined cohort of tumors that may serve as useful predictive or prognostic biomarkers of patient outcome. Further validation of the identified molecular markers may enable the future stratification of recurrent GBM patients into appropriate treatment regimens. Cancer Res; 76(3); 1–10. ©2016 AACR.

2 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RBRené Böttcher
René Böttcher
CKCharlotte F. Kweldam
Charlotte F. Kweldam
JLJulie Livingstone
Julie Livingstone
ELEmilie Lalonde
Emilie Lalonde
TYTakafumi N. Yamaguchi
Takafumi N. Yamaguchi
GLGeert J. L. H. van Leenders
Geert J. L. H. van Leenders
Invasive cribriform and intraductal carcinoma (CR/IDC) is associated with adverse outcome of prostate cancer patients. The aim of this study was to determine the molecular aberrations associated with CR/IDC in primary prostate cancer, focusing on genomic instability and somatic copy number alterations (CNA). Whole-slide images of The Cancer Genome Atlas Project (TCGA, N = 260) and the Canadian Prostate Cancer Genome Network (CPC-GENE, N = 199) radical prostatectomy datasets were reviewed for Gleason score (GS) and presence of CR/IDC. Genomic instability was assessed by calculating the percentage of genome altered (PGA). Somatic copy number alterations (CNA) were determined using Fisher-Boschloo tests and logistic regression. Primary analysis were performed on TCGA (N = 260) as discovery and CPC-GENE (N = 199) as validation set. CR/IDC growth was present in 80/260 (31%) TCGA and 76/199 (38%) CPC-GENE cases. Patients with CR/IDC and ≥ GS 7 had significantly higher PGA than men without this pattern in both TCGA (2.2 fold; p = 0.0003) and CPC-GENE (1.7 fold; p = 0.004) cohorts. CR/IDC growth was associated with deletions of 8p, 16q, 10q23, 13q22, 17p13, 21q22, and amplification of 8q24. CNAs comprised a total of 1299 gene deletions and 369 amplifications in the TCGA dataset, of which 474 and 328 events were independently validated, respectively. Several of the affected genes were known to be associated with aggressive prostate cancer such as loss of PTEN, CDH1, BCAR1 and gain of MYC. Point mutations in TP53, SPOP and FOXA1were also associated with CR/IDC, but occurred less frequently than CNAs. CR/IDC growth is associated with increased genomic instability clustering to genetic regions involved in aggressive prostate cancer. Therefore, CR/IDC is a pathologic substrate for progressive molecular tumour derangement.

14 October 2016 in Science
Verified
Journal Article
Closed access
PDF file
RSRomain A. Studer
Romain A. Studer
RRRicard A. Rodriguez-Mias
Ricard A. Rodriguez-Mias
KHKelsey M. Haas
Kelsey M. Haas
JHJoanne I. Hsu
Joanne I. Hsu
CVCristina Viéitez
Cristina Viéitez
JVJudit Villén
Judit Villén
Phosphorylation and fungal evolution: Phosphorylation after transcription modifies the activity of proteins. To understand how phosphorylation sites have evolved, Studer et al. studied a range of fungal species (see the Perspective by Matalon et al. ). Only a few sites were apparently present in the common ancestor of all 18 species investigated. Evolutionary age appeared to predict the potential functional importance of specific conserved phosphosites. Science , this issue p. 229 ; see also p. 176

31 August 2018 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
MKMalgorzata A Komor
Malgorzata A Komor
LBLinda Jw Bosch
Linda Jw Bosch
GBGergana Bounova
Gergana Bounova
ABAnne S Bolijn
Anne S Bolijn
PVPien Delis Van‐Diemen
Pien Delis Van‐Diemen
HWHarmen van de Werken
Harmen van de Werken
Consensus molecular subtyping is an RNA expression‐based classification system for colorectal cancer (CRC). Genomic alterations accumulate during CRC pathogenesis, including the premalignant adenoma stage, leading to changes in RNA expression. Only a minority of adenomas progress to malignancies, a transition that is associated with specific DNA copy number aberrations or microsatellite instability (MSI). We aimed to investigate whether colorectal adenomas can already be stratified into consensus molecular subtype (CMS) classes, and whether specific CMS classes are related to the presence of specific DNA copy number aberrations associated with progression to malignancy. RNA sequencing was performed on 62 adenomas and 59 CRCs. MSI status was determined with polymerase chain reaction‐based methodology. DNA copy number was assessed by low‐coverage DNA sequencing (n = 30) or array‐comparative genomic hybridisation (n = 32). Adenomas were classified into CMS classes together with CRCs from the study cohort and from The Cancer Genome Atlas (n = 556), by use of the established CMS classifier. As a result, 54 of 62 (87%) adenomas were classified according to the CMS. The CMS3 ‘metabolic subtype’, which was least common among CRCs, was most prevalent among adenomas (n = 45; 73%). One of the two adenomas showing MSI was classified as CMS1 (2%), the ‘MSI immune’ subtype. Eight adenomas (13%) were classified as the ‘canonical’ CMS2. No adenomas were classified as the ‘mesenchymal’ CMS4, consistent with the fact that adenomas lack invasion‐associated stroma. The distribution of the CMS classes among adenomas was confirmed in an independent series. CMS3 was enriched with adenomas at low risk of progressing to CRC, whereas relatively more high‐risk adenomas were observed in CMS2. We conclude that adenomas can be stratified into the CMS classes. Considering that CMS1 and CMS2 expression signatures may mark adenomas at increased risk of progression, the distribution of the CMS classes among adenomas is consistent with the proportion of adenomas expected to progress to CRC. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.